205 related articles for article (PubMed ID: 16933315)
21. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP
Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
[TBL] [Abstract][Full Text] [Related]
22. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription.
Stevens SJ; Smits PH; Verkuijlen SA; Rockx DA; van Gorp EC; Mulder JW; Middeldorp JM
AIDS; 2007 Oct; 21(16):2141-9. PubMed ID: 18090040
[TBL] [Abstract][Full Text] [Related]
23. Sensitivity and specificity of Epstein-Barr virus IGA titer in the diagnosis of nasopharyngeal carcinoma: a three-year institutional review.
Tsang RK; Vlantis AC; Ho RW; Tam JS; To KF; van Hasselt CA
Head Neck; 2004 Jul; 26(7):598-602. PubMed ID: 15229902
[TBL] [Abstract][Full Text] [Related]
24. Enhancing the efficiency of Epstein-Barr viral serologic test in the diagnosis of nasopharyngeal carcinoma.
Zhang C; Zong Y; Huang B; Sun Y; Ye Y; Feng K; Li J; Zhang F
Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):356-9. PubMed ID: 12408763
[TBL] [Abstract][Full Text] [Related]
25. [Quantitative analysis of plasma Epstein-Barr virus (EBV) DNA for monitoring of recurrence and metastasis in nasopharyngeal carcinoma patients after radiotherapy].
Li YH; Shao JY; Zhao MQ; Gao HY; Li LR; Guan ZZ; Zeng YX
Ai Zheng; 2003 Jun; 22(6):645-8. PubMed ID: 12948418
[TBL] [Abstract][Full Text] [Related]
26. [Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx].
Mazeron MC
Bull Cancer Radiother; 1996; 83(1):3-7. PubMed ID: 8679277
[TBL] [Abstract][Full Text] [Related]
27. Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area.
Kalpoe JS; Dekker PB; van Krieken JH; Baatenburg de Jong RJ; Kroes AC
J Clin Pathol; 2006 May; 59(5):537-41. PubMed ID: 16489178
[TBL] [Abstract][Full Text] [Related]
28. Epstein Barr virus (EBV) antibodies in the diagnosis of NPC--comparison between IFA and two commercial ELISA kits.
Chan SH; Soo MY; Gan YY; Fones-Tan A; Sim PS; Kaur A; Chew CT
Singapore Med J; 1998 Jun; 39(6):263-5. PubMed ID: 9803815
[TBL] [Abstract][Full Text] [Related]
29. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
[TBL] [Abstract][Full Text] [Related]
30. Epstein-Barr virus antibodies in patients with laryngeal and hypopharyngeal cancer.
Morshed K; Polz-Dacewicz M; Szymański M; Rajtar B; Ziaja-Sołtys M; Gołabek W
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(2):227-31. PubMed ID: 15323196
[TBL] [Abstract][Full Text] [Related]
31. Detection and analysis of anti-latent membrane protein 2A antibodies in the sera of patients with Epstein-Barr virus associated malignancies.
Chen Y; Yao K; Sun H; Qing J; Peng GY
Chin Med J (Engl); 2005 May; 118(9):725-30. PubMed ID: 15899133
[TBL] [Abstract][Full Text] [Related]
32. [Combined detection of Epstein-Barr virus antibodies for serodiagnosis of nasopharyngeal carcinoma].
Cai YL; Zheng YM; Wang W; Wei Y; Shen XX; Cheng JR; Wu YS; Gao JQ; Zhong WM; Li J
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Dec; 30(12):2746-8. PubMed ID: 21177196
[TBL] [Abstract][Full Text] [Related]
33. A retrospective cohort study of nasopharyngeal adenocarcinoma: a rare histological type of nasopharyngeal cancer.
Guo ZM; Liu WW; He JH
Clin Otolaryngol; 2009 Aug; 34(4):322-7. PubMed ID: 19673979
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus immune response in high-risk nasopharyngeal carcinoma families in Greenland.
Friborg J; Jarrett RF; Liu MY; Falk KI; Koch A; Olsen OR; Duncan P; Wohlfarht J; Chen JY; Melbye M
J Med Virol; 2007 Dec; 79(12):1877-81. PubMed ID: 17935169
[TBL] [Abstract][Full Text] [Related]
35. Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma.
Dardari R; Khyatti M; Benider A; Jouhadi H; Kahlain A; Cochet C; Mansouri A; El Gueddari B; Benslimane A; Joab I
Int J Cancer; 2000 Apr; 86(1):71-5. PubMed ID: 10728597
[TBL] [Abstract][Full Text] [Related]
36. Serum IgA antibodies to Epstein-Barr virus (EBV) early lytic antigens are present in primary EBV infection.
Bhaduri-McIntosh S; Landry ML; Nikiforow S; Rotenberg M; El-Guindy A; Miller G
J Infect Dis; 2007 Feb; 195(4):483-92. PubMed ID: 17230407
[TBL] [Abstract][Full Text] [Related]
37. Detection of Epstein-Barr virus DNA in plasma/serum: a useful serological indicator for diagnosis of nasopharyngeal carcinoma.
Mai S; Zong Y; Zhang M; Zhong B; Lin S
Chin Med J (Engl); 2002 Dec; 115(12):1895-7. PubMed ID: 12622949
[TBL] [Abstract][Full Text] [Related]
38. Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy: the potential role of quantitative analysis of circulating Epstein-Barr virus DNA.
Hong RL; Lin CY; Ting LL; Ko JY; Hsu MM
Cancer; 2004 Apr; 100(7):1429-37. PubMed ID: 15042677
[TBL] [Abstract][Full Text] [Related]
39. Epstein-Barr virus serology in early detection and screening of nasopharyngeal carcinoma.
Ng MH; Chan KH; Ng SP; Zong YS
Ai Zheng; 2006 Feb; 25(2):250-6. PubMed ID: 16480597
[TBL] [Abstract][Full Text] [Related]
40. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma.
Leung SF; Zee B; Ma BB; Hui EP; Mo F; Lai M; Chan KC; Chan LY; Kwan WH; Lo YM; Chan AT
J Clin Oncol; 2006 Dec; 24(34):5414-8. PubMed ID: 17135642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
